Clinical Trials
13
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety Study of Moxidectin in Adults With Scabies
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Medicines Development for Global Health
- Target Recruit Count
- 200
- Registration Number
- NCT05875441
- Locations
- 🇺🇸
LA Universal Research Center, Inc, Los Angeles, California, United States
🇺🇸Evolution Clinical Trials, Miami, Florida, United States
🇺🇸Medical Research of Westchester, Inc, Miami, Florida, United States
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
- Conditions
- Onchocerciasis
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Medicines Development for Global Health
- Target Recruit Count
- 12997
- Registration Number
- NCT04311671
- Locations
- 🇨🇩
Centre de Recherche pour les Maladies Tropicales Negligees, Rethy, Ituri, Congo, The Democratic Republic of the
🇨🇮Centre Suisse de Recherches Scientifiques en Coˆte d'Ivoire, Abidjan, Côte D'Ivoire
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Medicines Development for Global Health
- Target Recruit Count
- 36
- Registration Number
- NCT03962062
- Locations
- 🇬🇭
University of Health and Allied Services School of Public Health, Hohoe, Volta Region, Ghana
Dose-finding Study of Moxidectin for Treatment of Scabies
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Medicines Development for Global Health
- Target Recruit Count
- 22
- Registration Number
- NCT03905265
- Locations
- 🇦🇺
Royal Darwin Hospital, Darwin, Australia
🇦🇹Medizinischen Universität Wien, Vienna, Austria
🇫🇷Hopital Henri Mondor AP-HP, Créteil, France
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Medicines Development for Global Health
- Target Recruit Count
- 323
- Registration Number
- NCT03876262
- Locations
- 🇨🇩
Centre de Recherche pour les Maladies Tropicales Negligees, Rethy, Ituri, Congo, The Democratic Republic of the
- Prev
- 1
- 2
- Next
News
Ghana Approves Moxidectin as First River Blindness-Endemic Country
Ghana's FDA has approved moxidectin 2mg oral tablets for treating river blindness in adults and children aged 4 and older, marking a significant step in disease elimination.